P&
Academic Journal
Q1PharmacoEconomics & Outcomes News
Q1Ranking
—Impact Factor
15H-index
—SJR
—Research Score
—Coverage
About PharmacoEconomics & Outcomes News
PharmacoEconomics & Outcomes News is an academic journal listed in the JournalsWorld research directory. This profile includes verified journal identifiers, publisher information, research data, recent articles and official links where available.
Journal Metrics
RankingQ1
Impact Factor—
H-index15
SJR—
Research Score—
Coverage—
ISSN1173-5503, 1179-2043
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The journal publishes research related to Health Systems, Economic Evaluations, Quality of Life, Pharmaceutical Economics and Policy, Science, Research, and Medicine, Biotechnology and Related Fields, Healthcare Policy and Management, Educational Robotics and Engineering.
Recent Research Articles
Latest publications matched automatically by ISSN.
Monoclonal antibodies in metastatic colorectal cancer: benefits at high cost
2021-12 · DOI: 10.1007/s40274-021-08244-9Systemic sclerosis a significant patient and health resource economic burden
2021-12 · DOI: 10.1007/s40274-021-08260-7T2DM patients associated with substantial specialist expenditure in the Netherlands
2021-12 · DOI: 10.1007/s40274-021-08261-7Olaparib cost effective for in BRCA-mutated advanced ovarian carcinoma in Spain
2021-12 · DOI: 10.1007/s40274-021-08247-9SAPIEN 3 TAVI cost effective vs surgical valve replacement for severe aortic stenosis in France
2021-12 · DOI: 10.1007/s40274-021-08253-8Additional MRI more effective for initial staging in pancreatic cancer than standard imaging and less costly
2021-12 · DOI: 10.1007/s40274-021-08234-xNICE recommends osimertinib for NSCLC within Cancer Drugs Fund
2021-12 · DOI: 10.1007/s40274-021-08267-7Single-use clean intermittent catheters cost effective for managing neurogenic LUTD in Canada
2021-12 · DOI: 10.1007/s40274-021-08256-8Influenza vaccine cost effective in pregnant and older adults in Laos
2021-12 · DOI: 10.1007/s40274-021-08242-9Willingness to pay for cancer treatments and outcomes: QOL valued similarly to 1-year survival
2021-12 · DOI: 10.1007/s40274-021-08263-7ICER issues final evidence report for mavacamten for hypertrophic cardiomyopathy
2021-12 · DOI: 10.1007/s40274-021-08265-7Extending mammography screening to age 80 cost effective in USA?
2021-12 · DOI: 10.1007/s40274-021-08240-9UK's NICE updated guideline recommends progesterone to prevent early miscarriage
2021-12 · DOI: 10.1007/s40274-021-08268-7Systematic review: inconsistent methods for calculating informal care costs for dementia
2021-12 · DOI: 10.1007/s40274-021-08258-8Costs outside Swedish health system influence long-term value of DAA treatment for HCV
2021-12 · DOI: 10.1007/s40274-021-08236-xSGLT-2 inhibitors most cost effective for symptomatic and asymptomatic HFrEF
2021-12 · DOI: 10.1007/s40274-021-08255-8Concerns about rollout of inclisiran in primary care in England
2021-12 · DOI: 10.1007/s40274-021-08233-xPopulation genomic screening of all Australian adults for FH could be cost effective
2021-12 · DOI: 10.1007/s40274-021-08249-9Review of CEAs finds medical devices generally offer value for money
2021-12 · DOI: 10.1007/s40274-021-08252-8Barriers to prescription drug access within US commercial insurance
2021-12 · DOI: 10.1007/s40274-021-08264-7Reviews
Community Reviews
No approved community reviews yet. Be the first to contribute a verified experience.
Write a ReviewVersion History
Profile last updated
September 8, 2026 at 12:05 am
Profile published
September 8, 2026